Perceptive Advisors
DMK

Perceptive Advisors’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Perceptive Advisors’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,964
Closed -$481K – 129
2018
Q3 		$481K Buy
+1,964
New +$465K 0.01% 104
2017
Q3 		– Sell
-5,714
Closed -$2.08M – 157
2017
Q2 		$2.08M Buy
+5,714
New +$1.71M 0.1% 83

Other funds holding DMK

First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bard Associates
Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return
Oxford Asset Management
Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return
Leisure Capital Management
Leisure Capital Management Costa Mesa, California $320M AUM 39.11% 1-Year Est. Return

Perceptive Advisors's DMK Position: Q4 2018 in Review

Perceptive Advisors sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q4 2018, closing a stake of 1,964 shares — an estimated $481K sold.

Perceptive Advisors first reported a position in DMK in Q2 2017 and held it in 2 quarters. The position peaked at $2.08M in Q2 2017. 58 funds tracked by Wall St. Rank hold DMK as of Q4 2018.

  • Perceptive Advisors reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q4 2018 after selling out during the quarter.
  • Perceptive Advisors sold 1,964 DMK Pharmaceuticals Corporation Common Stock shares in Q4 2018, an estimated $481K.
  • Perceptive Advisors first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q2 2017 and held it in 2 quarters.
  • Perceptive Advisors's DMK Pharmaceuticals Corporation Common Stock position peaked at $2.08M in Q2 2017.
  • 58 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q4 2018.

Based on Perceptive Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.